Raymond James & Associates’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-1,993
| Closed | -$631K | – | 4078 |
|
|
2023
Q4 | $631K | Sell |
1,993
-408
| -17% | -$79.3K | ﹤0.01% | 2810 |
|
|
2023
Q3 | $406K | Sell |
2,401
-161
| -6% | -$30.3K | ﹤0.01% | 3015 |
|
|
2023
Q2 | $556K | Sell |
2,562
-525
| -17% | -$112K | ﹤0.01% | 2870 |
|
|
2023
Q1 | $561K | Sell |
3,087
-3
| -0.1% | -$574 | ﹤0.01% | 2847 |
|
|
2022
Q4 | $607K | Sell |
3,090
-27
| -0.9% | -$5.79K | ﹤0.01% | 2761 |
|
|
2022
Q3 | $701K | Sell |
3,117
-33
| -1% | -$6.68K | ﹤0.01% | 2612 |
|
|
2022
Q2 | $399K | Sell |
3,150
-2,278
| -42% | -$262K | ﹤0.01% | 3051 |
|
|
2022
Q1 | $688K | Sell |
5,428
-81
| -1% | -$9.12K | ﹤0.01% | 2862 |
|
|
2021
Q4 | $722K | Sell |
5,509
-29
| -0.5% | -$3.75K | ﹤0.01% | 2843 |
|
|
2021
Q3 | $677K | Sell |
5,538
-182
| -3% | -$21K | ﹤0.01% | 2848 |
|
|
2021
Q2 | $652K | Sell |
5,720
-18
| -0.3% | -$2.1K | ﹤0.01% | 2891 |
|
|
2021
Q1 | $690K | Sell |
5,738
-7
| -0.1% | -$793 | ﹤0.01% | 2772 |
|
|
2020
Q4 | $584K | Sell |
5,745
-229
| -4% | -$21.2K | ﹤0.01% | 2705 |
|
|
2020
Q3 | $462K | Sell |
5,974
-13
| -0.2% | -$1.11K | ﹤0.01% | 2686 |
|
|
2020
Q2 | $667K | Buy |
5,987
+2,358
| +65% | +$205K | ﹤0.01% | 2414 |
|
|
2020
Q1 | $261K | Sell |
3,629
-3,481
| -49% | -$298K | ﹤0.01% | 2861 |
|
|
2019
Q4 | $536K | Buy |
+7,110
| New | +$311K | ﹤0.01% | 2678 |
|
Other funds holding KRTX
Raymond James & Associates's KRTX Position: Q1 2024 in Review
Raymond James & Associates sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 1,993 shares — an estimated $631K sold.
Raymond James & Associates first reported a position in KRTX in Q4 2019 and held it in 17 quarters. The position peaked at $722K in Q4 2021. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.
- Raymond James & Associates reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Raymond James & Associates sold 1,993 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $631K.
- Raymond James & Associates first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2019 and held it in 17 quarters.
- Raymond James & Associates's Karuna Therapeutics, Inc. Common Stock position peaked at $722K in Q4 2021.
- 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Raymond James & Associates's 13F filing for Q1 2024, filed 22 Apr 2024.